Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 9, 2026, 11:15 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Naltrexone tablet Clear all
Completed Not applicable Interventional Accepts healthy volunteers

Exploratory Bioavailability of Fentanyl Sublingual Spray Under Fasting Conditions

NCT02138396
View directory record Official record
Conditions
Bioavailability
Interventions
Fentanyl Sublingual Spray (FSS), Fentanyl Citrate Injection (FCI), Naltrexone
Drug
Lead sponsor
INSYS Therapeutics Inc
Industry
Eligibility
18 Years to 55 Years
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Dec 11, 2014 · Synced Sep 9, 2026, 11:15 AM EDT
Completed Not applicable Interventional Results available

Effect of Naltrexone on Counterregulatory Mechanisms in Hypoglycemia

NCT01462227
View directory record Official record
Conditions
Hypoglycemia
Interventions
Naltrexone High Dose, Naltrexone Low Dose
Drug
Lead sponsor
Yale University
Other
Eligibility
18 Years to 55 Years
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Feb 17, 2016 · Synced Sep 9, 2026, 11:15 AM EDT
Terminated Phase 4 Interventional Accepts healthy volunteers Results available

IC PaIN Trial: Interstitial Cystitis Pain Improvement With Naltrexone

NCT04313972
View directory record Official record
Conditions
Interstitial Cystitis, Painful Bladder Syndrome, Bladder Pain Syndrome, Low Dose Naltrexone, Low-dose Naltrexone, Naltrexone
Interventions
low-dose naltrexone, Placebo oral tablet
Drug
Lead sponsor
Endeavor Health
Other
Eligibility
18 Years to 110 Years · Female only
Enrollment
3 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2023
U.S. locations
1
States / cities
Skokie, Illinois
Source: ClinicalTrials.gov public record
Updated Mar 6, 2025 · Synced Sep 9, 2026, 11:15 AM EDT
Terminated Phase 4 Interventional Results available

Naltrexone/Bupropion Cardiovascular Outcomes Study

NCT02638129
View directory record Official record
Conditions
Obesity, Cardiovascular Diseases
Interventions
Naltrexone HCl/Bupropion HCl ER, Placebo
Drug
Lead sponsor
Orexigen Therapeutics, Inc
Industry
Eligibility
18 Years and older
Enrollment
67 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016
U.S. locations
139
States / cities
Alexander City, Alabama • Auburn, Alabama • Birmingham, Alabama + 136 more
Source: ClinicalTrials.gov public record
Updated Feb 26, 2017 · Synced Sep 9, 2026, 11:15 AM EDT
Completed Phase 2 Interventional

Study to Evaluate the Subjective Effects of PTI-801 in Non-Physically Dependent Subjects With a History of Drug Abuse

NCT00734461
View directory record Official record
Conditions
Opioid-Related Disorders
Interventions
oxycodone and naltrexone
Drug
Lead sponsor
Pain Therapeutics
Industry
Eligibility
18 Years to 65 Years
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated May 1, 2016 · Synced Sep 9, 2026, 11:15 AM EDT
Enrolling by invitation No phase listed Observational

A Study to Evaluate the Safety of Exposure to Wegovy During Pregnancy

NCT05503927
View directory record Official record
Conditions
Pregnancy, Obesity, Overweight
Interventions
No Intervention
Other
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
15 Years to 50 Years · Female only
Enrollment
2,701 participants
Timeline
2020 – 2027
U.S. locations
2
States / cities
Ann Arbor, Michigan • Princeton, New Jersey
Source: ClinicalTrials.gov public record
Updated Jul 20, 2026 · Synced Sep 9, 2026, 11:15 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Bioequivalence Study Comparing Naltrexone SR/Bupropion SR Trilayer Tablets From Two Manufacturers

NCT02259179
View directory record Official record
Conditions
Healthy
Interventions
Reference naltrexone 8 mg SR/bupropion 90 mg SR combination trilayer tablets (2 tablets), Test naltrexone 8 mg SR/bupropion 90 mg SR combination trilayer tablets (2 tablets)
Drug
Lead sponsor
Orexigen Therapeutics, Inc
Industry
Eligibility
18 Years to 60 Years
Enrollment
80 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Dec 10, 2014 · Synced Sep 9, 2026, 11:15 AM EDT
Completed Phase 3 Interventional Results available

Individualized Obesity Pharmacotherapy

NCT03374956
View directory record Official record
Conditions
Obesity
Interventions
Phentermine-Topiramate, Liraglutide, Naltrexone/bupropion, Phentermine
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 75 Years
Enrollment
193 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jul 17, 2023 · Synced Sep 9, 2026, 11:15 AM EDT
Recruiting Early Phase 1 Interventional Accepts healthy volunteers

Understanding How Opioids Affect the Experiential and Neural Signatures of Social Experiences

NCT05007561
View directory record Official record
Conditions
Naltrexone, Placebo
Interventions
Naltrexone Hydrochloride, Placebo
Drug
Lead sponsor
San Diego State University
Other
Eligibility
18 Years to 25 Years
Enrollment
210 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2027
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Apr 12, 2026 · Synced Sep 9, 2026, 11:15 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Abuse Potential of Orally Administered Crushed Embeda Compared to Crushed Controlled-Release Morphine and Placebo in Non-Dependent Recreational Opioid Users

NCT01380093
View directory record Official record
Conditions
Nondependent Opioid Abuse, Episodic
Interventions
Placebo, MS Contin (morphine sulfate, controlled release), EMBEDA (morphine sulfate / naltrexone hydrochloride)
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 55 Years
Enrollment
80 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated May 30, 2012 · Synced Sep 9, 2026, 11:15 AM EDT
Completed Phase 1 Interventional

Augmenting Zyprexa With Naltrexone to Ameliorate Metabolic Side-Effects

NCT00567034
View directory record Official record
Conditions
Schizophrenia, Psychotic Disorders
Interventions
naltrexone, placebo
Drug
Lead sponsor
Mclean Hospital
Other
Eligibility
21 Years to 55 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2011
U.S. locations
1
States / cities
Belmont, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 24, 2013 · Synced Sep 9, 2026, 11:15 AM EDT
Not yet recruiting Phase 2 Interventional

Combination Therapy for Alcohol Use Disorder

NCT07249554
View directory record Official record
Conditions
Alcohol Use Disorder
Interventions
Placebo, Glucagon-Like Peptide-1 Agonist (GLP-1), Naltrexone (oral tablets)
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
21 Years to 65 Years
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Havre de Grace, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 12, 2026 · Synced Sep 9, 2026, 11:15 AM EDT
Terminated Phase 4 Interventional Results available

Naltrexone Treatment for Prolonged Grief Disorder (PGD)

NCT04547985
View directory record Official record
Conditions
Prolonged Grief Disorder
Interventions
Naltrexone HCl 50 MG Oral Tablet, Placebo
Drug
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Aug 27, 2024 · Synced Sep 9, 2026, 11:15 AM EDT
Completed Phase 4 Interventional

Naltrexone Maintenance Treatment of Alcoholism

NCT00000450
View directory record Official record
Conditions
Alcoholism
Interventions
Naltrexone Tablet, Matched Placebo Tablet
Drug
Lead sponsor
The Scripps Research Institute
Other
Eligibility
18 Years to 65 Years
Enrollment
159 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1997 – 2002
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Apr 19, 2017 · Synced Sep 9, 2026, 11:15 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Accelerated Development of Additive Pharmacotherapy Treatment for Methamphetamine Use Disorder

NCT01982643
View directory record Official record
Conditions
Methamphetamine Use Disorder
Interventions
naltrexone plus bupropion
Drug
Lead sponsor
Walter Ling
Other
Eligibility
18 Years to 65 Years
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
3
States / cities
Los Angeles, California • Honolulu, Hawaii • Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Mar 22, 2020 · Synced Sep 9, 2026, 11:15 AM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

Naltrexone and Hypoglycemia in Type 1 Diabetes

NCT01053078
View directory record Official record
Conditions
Type 1 Diabetes, Hypoglycemia Unawareness
Interventions
Naltrexone, Placebo
Drug · Other
Lead sponsor
University of Minnesota
Other
Eligibility
18 Years to 65 Years
Enrollment
29 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2014
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Feb 4, 2020 · Synced Sep 9, 2026, 11:15 AM EDT
Completed Phase 4 Interventional

Rapid Antidepressant Improvement Secondary to Excitatory Brain Responses

NCT04276259
View directory record Official record
Conditions
Major Depressive Disorder, Depression
Interventions
Buprenorphine, Naltrexone, Oral Placebo, IM Placebo, Theta burst stimulation (TBS) of the ventromedial prefrontal cortex.
Drug · Device
Lead sponsor
Marta Peciña, MD PhD
Other
Eligibility
18 Years to 55 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 30, 2026 · Synced Sep 9, 2026, 11:15 AM EDT
Completed Phase 4 Interventional Results available

Study of Naltrexone-Induced Blockade of Antidepressant Effects

NCT04322526
View directory record Official record
Conditions
Depression, Major Depressive Disorder
Interventions
Naltrexone 50 Mg Oral Tablet, Placebo oral tablet
Drug
Lead sponsor
Marta Peciña, MD PhD
Other
Eligibility
18 Years to 55 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 20, 2020 · Synced Sep 9, 2026, 11:15 AM EDT
Completed Phase 2 Interventional Results available

Combining Pregabalin (LYRICA®) With Lofexidine (LUCEMYRATM) to Treat OPIOID Withdrawal

NCT04218240
View directory record Official record
Conditions
Opioid Withdrawal
Interventions
Pregabalin 200 MG capsules, Placebo oral tablet, Lofexidine 0.18Mg Tab
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years to 70 Years
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
3
States / cities
Baltimore, Maryland • New York, New York • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Sep 18, 2024 · Synced Sep 9, 2026, 11:15 AM EDT
Completed Phase 4 Interventional Results available

Feasibility Study of Extended-release Naltrexone (Vivitrol) in Drug Court Settings

NCT02978417
View directory record Official record
Conditions
Opioid-Related Disorders
Interventions
Naltrexone for extended-release injectable suspension, Oral naltrexone
Drug
Lead sponsor
Duke University
Other
Eligibility
18 Years to 65 Years
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Raleigh, North Carolina
Source: ClinicalTrials.gov public record
Updated Jun 15, 2020 · Synced Sep 9, 2026, 11:15 AM EDT
Recruiting Phase 2Phase 3 Interventional

Efficacy of Buprenorphine and XR-Naltrexone Combination for Relapse Prevention in Opioid Use Disorder

NCT05011266
View directory record Official record
Conditions
Opioid-use Disorder
Interventions
Buprenorphine/naloxone, Placebo
Drug
Lead sponsor
New York State Psychiatric Institute
Other
Eligibility
18 Years to 65 Years
Enrollment
180 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
2
States / cities
Rockville, Maryland • New York, New York
Source: ClinicalTrials.gov public record
Updated May 18, 2026 · Synced Sep 9, 2026, 11:15 AM EDT
Completed Phase 3 Interventional Results available

Method-of-Use Study Assessing the Effect of Naltrexone Sustained Release (SR)/ Bupropion SR on Body Weight and Cardiovascular Risk Factors in Overweight and Obese Subjects

NCT01764386
View directory record Official record
Conditions
Obesity, Overweight
Interventions
NB, CLI, Usual Care
Drug · Behavioral
Lead sponsor
Orexigen Therapeutics, Inc
Industry
Eligibility
18 Years to 60 Years
Enrollment
242 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
15
States / cities
Denver, Colorado • St Louis, Missouri • Cary, North Carolina + 12 more
Source: ClinicalTrials.gov public record
Updated Dec 28, 2015 · Synced Sep 9, 2026, 11:15 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

The Effect of Buprenorphine Delivered by Buprenorphine Transdermal System (BTDS) at Doses up to 80 Micrograms/Hour (mcg/hr) and Naltrexone on Electrocardiogram (ECG) Intervals in Healthy Volunteers

NCT01999114
View directory record Official record
Conditions
ECG Effects
Interventions
Buprenorphine transdermal patch, Naltrexone tablet, Placebos (for TDS and for naltrexone and for moxifloxacin), Moxifloxacin tablet
Drug
Lead sponsor
Purdue Pharma LP
Industry
Eligibility
18 Years to 55 Years
Enrollment
328 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Nov 4, 2018 · Synced Sep 9, 2026, 11:15 AM EDT
Completed No phase listed Observational Results available

Real-World Evidence on the Cardiovascular Safety of CONTRAVE® in the United States (U.S.)

NCT06090461
View directory record Official record
Conditions
Obesity
Interventions
Not listed
Lead sponsor
Currax Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
31,889 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2022
U.S. locations
1
States / cities
Brentwood, Tennessee
Source: ClinicalTrials.gov public record
Updated Jun 24, 2025 · Synced Sep 9, 2026, 11:15 AM EDT